Bio-Path Hldgs Inc Stock Price, News & Analysis

Bio-Path Holdings (BPTH) announced a poster presentation at the 2021 American Society of Hematology (ASH) Annual Meeting from December 11-14, 2021. The presentation will feature safety and preliminary efficacy data from the Phase 2 trial of prexigebersen (BP1001), targeting acute myeloid leukemia. Dr. Maro Ohanian from M.D. Anderson Cancer Center will lead the presentation on December 11, detailing the therapy's safety and efficacy in patients with high-risk and relapsed/refractory AML. This event is pivotal for showcasing BPTH's innovative drug development.

Bio-Path Holdings has received FDA clearance for its IND application to start a Phase 1/1b clinical trial of prexigebersen-A targeting solid tumors, including ovarian and triple negative breast cancer. This marks a significant milestone as the company advances its fourth drug candidate into clinical testing. Preclinical trials showed a promising 86% decrease in tumor burden with no toxicity noted in animal studies. The trial will treat patients using a 3+3 design across multiple cancer centers, beginning with six evaluable patients.

Bio-Path Holdings has received FDA clearance for the IND application of BP1002, its second drug candidate, which aims to treat refractory/relapsed acute myeloid leukemia (AML). This Phase 1/1b clinical trial will evaluate BP1002's efficacy targeting the Bcl-2 protein. The trial is expected to involve several leading cancer centers, starting with six evaluable patients. Preclinical studies suggest BP1002 combined with decitabine may benefit patients resistant to current therapies. The study’s design includes a 3+3 model, with a starting dose of 20 mg/m² administered twice weekly.

Bio-Path Holdings (NASDAQ:BPTH) announced its Q2 2021 financial results, reporting a net loss of $1.8 million or $0.26 per share, an improvement from a loss of $2.0 million in Q2 2020. The company has made strides in advancing its DNAbilize portfolio, notably being granted a new U.S. patent for its BP1003 program. Additionally, cash reserves increased to $28.1 million as of June 30, 2021, compared to $13.8 million at the end of 2020. A conference call is scheduled for today at 8:30 A.M. ET to discuss these developments.

Bio-Path Holdings, Inc. (NASDAQ: BPTH) announced a live conference call scheduled for August 13, 2021, at 8:30 a.m. ET. During this call, the company will report its financial results for Q2 ended June 30, 2021, and discuss its business overview. Bio-Path is focused on developing its DNAbilize^® antisense RNAi nanoparticle technology, with its lead candidate, prexigebersen, currently in Phase 2 studies for blood cancers. The company is also preparing for FDA consideration of prexigebersen-A for solid tumors and has ongoing studies for BP1002 in lymphoma.

Bio-Path Holdings (NASDAQ:BPTH) announced the granting of a new patent by the U.S. Patent and Trademark Office for BP1003, an innovative cancer treatment designed to inhibit STAT3 expression. This patent (U.S. Patent No. 11,041,153) reinforces the company's proprietary DNAbilize technology, aimed at enhancing drug delivery for difficult-to-treat cancers like pancreatic cancer and acute myeloid leukemia. The company aims to advance BP1003's development in pancreatic cancer next year.

Bio-Path Holdings (NASDAQ: BPTH) announced encouraging Q1 2021 financial results with a net loss of $2.4 million ($0.43 per share), an improvement from $3.3 million ($0.90 per share) in Q1 2020. The company successfully completed the safety run-in of Stage 2 in its Phase 2 clinical trial for prexigebersen in treating acute myeloid leukemia (AML). Additionally, Bio-Path raised $13 million in a public offering, significantly increasing cash reserves to $30.8 million. Recent data presentations at notable conferences have bolstered awareness of its DNAbilize platform for cancer treatment.

Bio-Path Holdings, Inc. (NASDAQ: BPTH) announced a live conference call and audio webcast scheduled for May 14, 2021, at 8:30 a.m. ET to discuss its financial results for Q1 2021, which ended on March 31, 2021, along with a business overview. The company's proprietary DNAbilize^® antisense RNAi nanoparticle technology is being utilized to develop targeted cancer drugs, including its lead candidate, prexigebersen, currently in Phase 2 trials for blood cancers. This event will be accessible via phone or on the company's website.

Bio-Path Holdings announced the publication of a peer-reviewed article in Biomedicines, discussing challenges in antisense oligonucleotide drug delivery and highlighting the advantages of prexigebersen (BP1001). The authors emphasized prexigebersen's potential to address delivery challenges due to its unique properties, including stability and non-toxicity. Currently, prexigebersen is in a Phase 2 study targeting blood cancers, while a modified version is being considered for Phase 1 studies in solid tumors. The breakthrough technology could significantly enhance cancer treatment.